What is Zacks Research's Estimate for TEVA FY2024 Earnings?

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) - Stock analysts at Zacks Research raised their FY2024 earnings estimates for shares of Teva Pharmaceutical Industries in a note issued to investors on Monday, November 4th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $2.30 for the year, up from their previous forecast of $2.29. The consensus estimate for Teva Pharmaceutical Industries' current full-year earnings is $2.33 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries' Q4 2024 earnings at $0.67 EPS, Q3 2026 earnings at $0.79 EPS and FY2026 earnings at $2.77 EPS.

A number of other equities analysts also recently commented on the stock. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research report on Thursday, October 17th. JPMorgan Chase & Co. increased their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a "neutral" rating in a research note on Monday, October 21st. UBS Group lifted their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a "buy" rating in a research note on Tuesday, September 3rd. Barclays increased their price objective on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 23rd. Finally, Argus upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating and set a $20.00 target price on the stock in a research report on Wednesday, July 10th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $19.67.

Teva Pharmaceutical Industries Stock Performance

Teva Pharmaceutical Industries stock traded up $0.07 during mid-day trading on Thursday, reaching $17.50. 11,505,912 shares of the company were exchanged, compared to its average volume of 9,301,146. Teva Pharmaceutical Industries has a twelve month low of $8.55 and a twelve month high of $19.31. The company has a debt-to-equity ratio of 2.52, a quick ratio of 0.59 and a current ratio of 0.89. The firm's 50-day simple moving average is $18.00 and its two-hundred day simple moving average is $17.06. The firm has a market cap of $19.83 billion, a PE ratio of -44.69, a price-to-earnings-growth ratio of 1.34 and a beta of 0.87.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported $0.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.63 by $0.04. The business had revenue of $4.33 billion for the quarter, compared to analyst estimates of $4.08 billion. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%.

Institutional Trading of Teva Pharmaceutical Industries

Large investors have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC boosted its stake in Teva Pharmaceutical Industries by 26.8% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 36,753 shares of the company's stock worth $519,000 after buying an additional 7,763 shares during the last quarter. Nordea Investment Management AB lifted its stake in shares of Teva Pharmaceutical Industries by 3.0% in the 1st quarter. Nordea Investment Management AB now owns 91,837 shares of the company's stock valued at $1,299,000 after purchasing an additional 2,701 shares in the last quarter. Daiwa Securities Group Inc. grew its holdings in shares of Teva Pharmaceutical Industries by 3.7% during the 1st quarter. Daiwa Securities Group Inc. now owns 115,693 shares of the company's stock worth $1,632,000 after purchasing an additional 4,170 shares during the period. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Teva Pharmaceutical Industries during the 1st quarter worth approximately $93,000. Finally, SG Americas Securities LLC raised its holdings in Teva Pharmaceutical Industries by 12.0% in the first quarter. SG Americas Securities LLC now owns 610,407 shares of the company's stock valued at $8,613,000 after buying an additional 65,529 shares during the period. Institutional investors and hedge funds own 54.05% of the company's stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.